On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) as a booster for adults.

This recommendation gives people ages 18 years and older the option to receive the Novavax COVID-19 Vaccine, Adjuvanted as a booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna booster if they have completed primary series vaccination but have not previously received a COVID-19 booster, and if they cannot or will not receive mRNA vaccines.